Apricot Therapeutics AG hat dies direkt geteilt
This is a big stepping stone by our founder Lucas Pelkmans in collaboration with scientists at University of Zurich and ETH Zürich towards predictive functional precision medicine. Being able to predict the complex responses of individual cells to drugs using our proprietary 4i technology will revolutionize clinical decision making. Congratulations to all involved!!
🥁 “The paper is a significant step forward in terms of understanding the heterogeneous response of different cell states to environmental perturbations. It may impact drug discovery in the future.” ‘Predicting how single cells react to perturbations’ is one of the #SIBRemarkableOutputs 2023 👏 This work joins the yearly list of outstanding contributions from SIB Members across Switzerland to the field of #bioinformatics. 👉 Discover this shortlist of outstanding works: https://lnkd.in/din23W7N #CellOT #MachineLearning 💡 The SIB Remarkable Outputs gather on a shortlist the most outstanding works produced by SIB members each year. These contributions showcase the latest advances in the Swiss bioinformatics field and include innovative solutions to share with the life science community. BioAlps - Swiss Health Valley, ELIXIR, Life Sciences Switzerland (LS2), Luciano Cascione, Laurent Falquet, Robert Ivánek, Charlotte Soneson, Patricia Palagi Graf, Frederique Lisacek, Robert Waterhouse, ETH AI Center, ETH Zürich, University of Zurich, Charlotte Bunne, Gabriele Gut, Stefan Stark, Kjong Lehmann, Jacobo Sarabia del Castillo, Mitch Levesque, Lucas Pelkmans, Andreas Krause, Gunnar Rätsch